1. Introduction {#sec1}
===============

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. Although there have been landmark targeted therapies developed in other hematologic malignancies, such as imatinib for chronic myeloid leukemia and ibrutinib in chronic lymphocytic leukemia, induction chemotherapy for AML has not changed significantly for several decades \[[@B1], [@B2]\]. The notable exception being acute promyelocytic leukemia (APL) with the development of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) to overcome the block in myeloid differentiation due to the PML-RAR*α* fusion protein created by the translocation 15;17. Current AML induction therapies are successful in obtaining complete remission in approximately 75% of young (age \< 60 years) de novo AML patients; however, most are destined to relapse. This clinical behavior suggested the presence of an underlying leukemic cell population responsible for the relapsing nature of AML despite the attainment of a complete remission through induction chemotherapy. The existence of leukemic stem cells in AML capable of recapitulating the disease was firmly established by transplant experiments utilizing immunocompromised mouse models two decades ago \[[@B3], [@B4]\]. To date, the knowledge derived from the discovery of leukemic AML stem cells is just beginning to be used in developing new therapeutic strategies and categorizing risk groups in patients. Patient outcomes in CN-AML, in particular, are widely diverse. The clinical validation of several additional molecular markers such as*FLT3*,*NPM1,* and*CEBPA* mutations has added a great deal to the prognostic stratification of CN-AML. Therefore, it is vital to build upon these advances by continuing to elucidate the biological characteristics and properties of leukemic stem cells and their regulating factors to assess their impact on AML treatment plans, the overarching question being what is the optimal consolidation strategy for each AML patient? Perhaps the incorporation of leukemia-stem cell mutations will add further clarity to which patients merit consolidation with allo-HCT and its attendant mortality and comorbidity and which AML patients can be safely managed with chemotherapy alone.

Historically, the French American British (FAB) classification system was used to subdivide AML into 8 subgroups (M0--M7) on a morphological basis \[[@B5]\]. The advent of cytogenetic studies enabled AML subtypes to be stratified into three risk groups, favorable, intermediate, and unfavorable risk. Using cytogenetics, clinicians could identify the favorable risk AML, such as the core binding factor leukemias \[inv(16), t(16;16), and t(8;21)\], and for this risk group, excellent long-term survival could be achieved with high dose cytarabine consolidation therapy alone. For patients with unfavorable risk, such as monosomies, 17p deletion, or complex abnormalities, there is a very low likelihood of cure with chemotherapy alone and consolidation with allo-HSCT is pursued if possible. Intermediate-risk patients include CN-AML, which comprises up to 40% to 50% of AML patients \[[@B6]\]. The clinical outcome of CN-AML patients varies widely and cannot be predicted based solely on cytogenetics.

The focus on improving our understanding of CN-AML prognosis and outcomes leads to the identification additional molecular markers of clinical significance. Mutations in nucleophosmin 1*(NPM1)*, fetal liver tyrosine kinase 3*(FLT3),* and CCAAT/enhancer binding protein *α (CEBPA)* have been shown to have clinically significant prognostic value \[[@B7]\]. The*FLT3* internal tandem duplication (ITD) mutation (*FLT3*^ITD^) is present in nearly one-third of AML cases and has been associated with adverse clinical outcomes including increased relapse risk and decreased overall survival (OS) \[[@B8]\].*FLT3*^ITD^ presence in CN-AML identified a subgroup of patients with more adverse outcome, particularly patients with a high mutant allelic frequency \[[@B9]\]. In addition to providing prognostic information, the*FLT3*^ITD^ is a therapeutic target as well. Sorafenib, a tyrosine kinase inhibitor targeting*FLT3*^ITD^ mutations, has been shown to increase event-free survival (EFS) and relapse-free survival (RFS) when added to both induction and consolidation therapies, although there was no OS benefit in the three years of follow-up in the newly diagnosed AML patients aged 60 years or younger \[[@B10]\].*NPM1* mutation has also been recently validated as a molecular marker of minimal residual disease (MRD) in*NPM1* mutation positive patients and the presence of MRD was shown to be the only independent prognostic factor for death in multivariate analysis \[[@B11]\].

Consolidative chemotherapy is utilized to eliminate residual leukemia cells and/or leukemic stem cells (LSC) after induction chemotherapy to reduce the chance of relapse. Risk of a relapse after induction chemotherapy and consolidation chemotherapy increases with the increased MRD, a condition which can be assessed by immunophenotypical detection of leukemia cells \[[@B12], [@B13]\]. Level of MRD correlates with the amount of leukemic stem cells and predicts outcome in AML \[[@B14]--[@B17]\]. Therefore, it is imperative to keep leukemic stem cells in mind when clinicians stratify patients for treatment purposes.

Advances in clinical genomics have identified an expanding array of recurrent molecular lesions in AML that will add layers of complexity to prognostic stratification needed to guide treatment and provide needed targets for new AML therapies. The evolving challenge is to incorporate these molecular abnormalities and their combinatorial effect on AML prognosis and in turn treatment strategies. The availability of this new AML data has created a requirement of a new classification system based on both cytogenetics and additional molecular lesions, which will be pivotal in establishing new clinical treatment guidelines. Furthermore, new classifications based on molecular abnormalities may help clinical trial design to develop targeted therapies to specific subgroups of AML patients. Recently a new AML classification system has been proposed by Papaemmanuil et al. \[[@B18]\]. Here the authors classified AML based on the presence of one or more driver mutations +/− other comutations into 11 different subgroups and correlated with clinical outcomes. This new classification system has provided insight regarding the effects of specific driver mutations and the additive effect seen when they are found in combination. In this paper, we summarize the significance of the most clinically relevant molecular mutations, cooccurrences of these mutations, and their functional role on leukemic stem cell population in relation to clinical outcomes based on this newly developed classification system.

2. The New AML Classification System {#sec2}
====================================

The proposed new AML classification system is based on a retrospective genomic analysis of 1540 AML patients in three prospective trials of the German-Austrian AML Study Group \[[@B18]\]. Patients received induction chemotherapy with idarubicin, cytarabine, and etoposide (ICE) with or without ATRA; high-risk patients were offered allo-HCT; intermediate-risk patients were offered a matched related donor allo-HCT, if a matched sibling was available; low risk patients received chemotherapy alone. The median follow-up period was 5.9 years.

In addition to cytogenetic analyses, 111 candidate driver genes were sequenced and 5234 somatic driver mutations were identified across 76 genes or genomic regions. Nearly all AML patients (96%) had at least one mutation and 86% patients were found to have two or more mutations. Statistical analysis of comutation patterns was utilized to define 11 mutually exclusive AML subtypes including three novel genetic subgroups that have not been described in the World Health Organization (WHO) classification in 2008 \[[@B19]\]. These novel subgroups are, namely, (1) AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (18% of patients); (2) AML with*TP53* mutations, chromosomal aneuploidies, or both (13%); and (3) AML with*IDH2*^R172^ mutations (1%). Many of the mutations used to define the novel subgroups involve genes which have roles in stem cell functions. Of note, only 48% of patients were classifiable based on the current WHO guidelines, whereas 80% of patients could be allocated into this novel classification system. Only 8% of patients had either no detected driver mutations (4%) or ≥2 genomic subgroups (4%).

Clinical outcomes, such as OS of AML patients with genetic mutations, were found to be significantly altered by the presence or absence of other driver mutations as has been described by others \[[@B20]\]. For instance,*NPM1*-mutated AML, as the largest subgroup in this novel classification, had variable clinical outcomes influenced by the presence of concurrent mutations such as*FLT3*,*DNMT3A*,*NRAS*,*IDH*,*PTPN11*, or chromatin-spliceosome mutations. We focused on the clinical outcomes of the most significant single or concurrent molecular mutations based on this novel classification ([Table 1](#tab1){ref-type="table"}) and the significance of concurrent or mutually exclusive alterations in genes of interest ([Table 2](#tab2){ref-type="table"}). We did not include the effect of traditional cytogenetic abnormalities in this study.

3. AML with*NPM1* Mutation {#sec3}
==========================

Nucleophosmin is a protein encoded by the*NPM1* gene in humans. Nucleophosmin has multiple functions in various processes including histone chaperones, ribosome biogenesis and transport, genomic stability and DNA repair, control of centrosome duplications, and regulation of the ARF-p53 tumor suppressor pathway \[[@B21]\]. All these functions have a part in leukemic stem cell self-renewal and limited differentiation. Indeed, stem cell/progenitor cell surface marker CD34+ cells from*NPM1*-mutated AML patients are able to recapitulate leukemia in immunodeficient mice \[[@B22]\]. Alteration of the*NPM1* gene was found to be present at a high frequency in AML patients, ranging from 25% to 53% in all AML and 46% to 67% in CN-AML.*NPM1*-mutated AML consists of 27% of all AML and therefore forms the largest subgroup in this novel classification \[[@B18]\]. The identification of*NPM1* mutation in AML is important for both disease prognosis and the subsequent treatment decision-making regarding consolidation with chemotherapy alone or an allo-HCT treatment. Furthermore, a recent study demonstrated the importance of MRD analysis in*NPM1*-mutated AML \[[@B11]\]. Since high MRD correlates positively with high stem cell frequency in AML \[[@B16]\], persistence of*NPM1*-mutated transcripts in blood was associated with a greater risk of relapse after 3 years of follow-up.

AML with*NPM1* mutation is a clinically heterogeneous group likely due to the prevalence of concurrent mutations: 54%*DNMT3A*, 39%*FLT3*^ITD^, 19%*NRAS*, 16%*TET2,* and 15%*PTPN11*.*NPM1* is usually a secondary or downstream mutation, whereas mutations in*DNMT3A*,*ASXL1*,*IDH1*/*2*, and*TET2* occur very early during clonal evolution but are typically not sufficient to cause leukemia on their own. Therefore, the analysis of comutation patterns in this group has become crucial in predicting disease prognosis.

3.1. *NPM1* and*FLT3*^ITD^ {#sec3.1}
--------------------------

*FLT3* ^ITD^ represents one of the most frequent genetic alterations with a 20% frequency in adult AML, 28--34% in cytogenetically normal AML \[[@B23]\], and 39% in*NPM1*-mutated AML \[[@B18]\].*FLT3*^ITD^ activates STAT5 to maintain survival of leukemic stem cell population in AML \[[@B24]\]. It was not a surprise that*FLT3*^ITD^-positive AML patients had higher relapse incidence and lower DFS \[[@B25], [@B26]\] as well as OS \[[@B27]\]. These observations have validated*FLT3* as a therapeutic target in AML and*FLT3* inhibitors have shown promising results when combined with standard therapy \[[@B10], [@B28]\].

With regard to*NPM1* and*FLT3*^ITD^, several studies have shown that AML with*NPM1* mutation, but without*FLT3*^ITD^ mutation, is associated with significantly better OS and EFS \[[@B29]--[@B32]\]; one study demonstrated that*NPM1* mutation with or without*FLT3*^ITD^ was only favorable in achieving complete remission but was associated with a high relapse rate with no OS and EFS benefits \[[@B33]\]. The German-Austrian AML Study Group conducted a study to evaluate genetic mutations and clinical outcomes in 872 adults younger than 60 years of age and again demonstrated that*NPM1* mutation without*FLT3*^ITD^ was associated with lower risk of relapse and death \[[@B34]\]. The majority of these earlier studies showed that*NPM1* mutation without*FLT3*^ITD^ is associated with better clinical outcomes, and allo-HST conferred no benefit in this patient group \[[@B34]\] similar to the core binding-factor leukemia patient group \[[@B35]\]. It is apparent that all these studies pointed to a worse clinical outcome when*NPM1*mutation and*FLT3*^ITD^ mutation coexisted in AML. However, the most recent study argued against*NPM1* and*FLT3*^ITD^ mutations being the sole determinants in AML prognosis, and another mutation,*DNMT3A*, must also be taken into consideration in the decision-making process of the treatment of*NPM1*-mutated AML \[[@B18]\].

3.2. *NPM1* and*DNMT3A* {#sec3.2}
-----------------------

*DNMT3A* (DNA methyltransferase 3A) is an enzyme that catalyzes the transfer of methyl groups to specific CpG structures in DNA and hence plays an essential role in DNA methylation and gene silencing regulatory processes \[[@B36]\].*DNMT3A* is important in normal hematopoietic stem cell differentiation and self-renewal \[[@B37]\] and its mutation produces a reservoir of preleukemic stem cells which can evolve into AML \[[@B38]\].*DNMT3A* mutations were found in 22.1% of all AML and 33.7% of AML with intermediate-risk cytogenetic profile and were independently associated with a poor outcome regardless of age \[[@B39]\].*DNMT3A* mutations tend to cooccur with*FLT3*,*TET2*, or*IDH1* in AML ([Table 2](#tab2){ref-type="table"}). The combination of*DNMT3A* mutation with*FLT3*,*TET2*, or*IDH1* tends to have an adverse effect on disease-free survival in AML compared to wild-type group ([Figure 1](#fig1){ref-type="fig"}). Interestingly, hypomethylating agents, such as decitabine and 5-azacitidine, have a higher clinical remission rate in*DNMT3A*-mutated AML \[[@B40]\].

Patients with*DNMT3A*,*TET2*,*ASXL1*,*PHF6*, or*MLL*^PTD^ mutations who were in the WHO intermediate group had an adverse outcome compared to those with other genotypes \[[@B27]\].*DNMT3A* mutation was found to be an adverse prognostic factor in cytogenetically normal AML with mutated*NPM1* without*FLT3*^ITD^ in terms of OS \[[@B41]\]. However, this finding was not confirmed by the most recent study \[[@B18]\]. Instead, it was reported that patients with both*NPM1* and*DNMT3A* mutations but without*FLT3*^ITD^ showed much better outcomes than those with*FLT3*^ITD^. Therefore, triple-mutated AML (*NPM1*/*DNMT3A*/*FLT3*^ITD^) yields the worst prognosis and the consolidation with allo-HCT should be considered, although prospective study is needed to confirm these results.

3.3. *NPM1* and*NRAS*^G12/13^ {#sec3.3}
-----------------------------

*NRAS* belongs to the RAS GTPase family of genes. It plays important roles in the regulation of proliferation, differentiation, and apoptosis in AML and is a fairly common mutation in AML ranging from 11% to 30% \[[@B42]\].*NRAS* mutation consists of 19% of*NPM1*-mutated AML \[[@B18]\]. The prognostic impact of*NRAS* mutation has been reported to be insignificant for OS, EFS, and disease-free survival (DFS) \[[@B42]\]. However more recently mutations in*NPM1* and*DNMT3A* in the presence of*NRAS*^G12/13^ in AML patients were associated with a more favorable outcome \[[@B18]\].

3.4. *NPM1* and*TET2* {#sec3.4}
---------------------

*TET2* (ten-eleven translocation) protein is an epigenetic modifier that converts methylcytosine to 5-hydroxymethylcytosine and plays a role in DNA methylation and myelopoiesis. Normal expression and function of*TET2* are essential in maintaining the hematopoietic stem cell (HSC) pool and in controlling HSC differentiation \[[@B43]\]. Studies using conditional knockout mouse models have revealed that complete loss of*TET2 (TET2*^−/−^) or*TET2* haplodeficiency*(TET2*^+/−^) impaired hematopoietic stem cell differentiation, held cells in a more immature state, and initiated aberrant hematopoiesis both in vitro and in vivo \[[@B44]--[@B46]\].*TET2* expression is tightly regulated by the master stem cell transcription factors*Oct4* and*Sox2* \[[@B44]\].*TET2* mutations are present in 5--25% of adult AML cases, with the highest frequency in the elderly \[[@B47], [@B48]\].*TET2* mutations are significantly correlated with*NPM1* (16%) in this most recent study \[[@B18]\] and were found to be mutually exclusive with*MLL*^PTD^ \[[@B48]\] and*IDH1*/*2* mutations \[[@B48], [@B49]\].*TET2* mutation resulted in a lower complete remission rate, shorter EFS and DFS in patients with mutated*NPM1* without*FLT3*^ITD^ \[[@B47]\], and shorter OS in patients with mutated*NPM1* without*FLT3*^ITD^ \[[@B47], [@B50]\] and with mutated*NPM1* \[[@B50]\]. However,*TET2* mutations were also reported to have no impact on the clinical outcomes of de novo AML \[[@B48], [@B49]\], CN-AML \[[@B49], [@B50]\], and CN-AML with mutated*NPM1* or*CEBPA* without*FLT3*^ITD^ \[[@B41]\]. The full clinical impact of*TET2* mutations has yet to be fully understood.

3.5. *NPM1* and*IDH1/IDH2*^R140^ {#sec3.5}
--------------------------------

*IDH1* and*IDH2* (isocitrate dehydrogenases 1 and 2) are enzymes that catalyze the interconversion of isocitrate and alpha-ketoglutarate and appear to play an epigenetic role in histone and possibly DNA methylation.*IDH1* or*IDH2* mutations confer a hypermethylation phenotype in leukemia and inhibit hematopoietic stem cell differentiation \[[@B51]\]. These phenotypic characteristics are shared by*TET2* loss-of-function mutations \[[@B46]\]. The most common*IDH1* mutation is in the arginine residue at position 132 (*IDH1*^R132^), occurring in 6--9% of adult AML, while*IDH2* mutations occur in 9--19%, predominantly*IDH2*^R140^ in 8--12% \[[@B18], [@B27], [@B52]--[@B54]\].*IDH1* and*IDH2* mutations are mutually exclusive in AML. Furthermore,*IDH1* and*IDH2*^R140^ are strongly associated with*NPM1* mutations \[[@B18]\].*IDH1* \[[@B53], [@B54]\] and*IDH2* \[[@B53]\] mutations have been reported to carry an unfavorable prognosis with regard to survival in normal karyotype AML lacking*NPM1* and*FLT3*^ITD^ mutations. In patients with cooccurring*DNMT3A* and*IDH2*^R140^ mutations, the OS was significantly poorer than those with wild-type or a single mutation \[[@B18]\].

An earlier study demonstrated that the*IDH1* and*IDH2* mutations constitute poor prognostic factors in cytogenetically normal AML with*NPM1* mutation without*FLT3*^ITD^ \[[@B55]\]. In some other studies, however, patients with mutated*IDH1* or*IDH2*^R140^ had good prognoses for OS in AML patients with the*NPM1* mutation without*FLT3*^ITD^ \[[@B27], [@B52]\], and it was further concluded that the favorable effect of*NPM1* mutations was restricted to patients with cooccurring*NPM1* and*IDH1* or*IDH2*^R140^ mutations \[[@B27]\].

4. AML with Mutated Chromatin, RNA-Splicing Genes, or Both {#sec4}
==========================================================

This chromatin-spliceosome group is the second largest subgroup in this new classification \[[@B18]\]. This is also an extremely heterogeneous group, consisting of genes regulating RNA splicing (*SRSF2*,*SF3B1*,*U2AF1*, and*ZRSR2*), chromatin (*ASXL1*,*STAG2*,*BCOR*,*MLL*^PTD^,*EZH2*, and*PHF6*), and transcription*(RUNX1)*. Functional proteins encoded by these genes have functions in hematopoietic stem cell self-renewal and differentiation. Using the European LeukemiaNet (ELN) guidelines, the majority (84%) of the patients in this new chromatin-spliceosome group would be classified as having intermediate prognostic risk. However, this new subgroup demonstrated resistance to induction chemotherapy and inferior long-term outcomes \[[@B18]\] suggesting a reclassification of AML patients with chromatin-spliceosome mutations as an adverse prognostic group. Nearly all of the genetic mutations in this subgroup have been previously reported to be adverse prognostic markers.

4.1. *RUNX1* {#sec4.1}
------------

The*RUNX1* (runt-related transcription factor 1, formerly known as AML1) gene encodes the alpha subunit of the core binding factor involved in transcription and is required for definitive hematopoiesis \[[@B56]\].*RUNX1* protein also plays an essential role in mesenchymal stem cell proliferation and promotes cell survival in AML \[[@B57], [@B58]\].*RUNX1* mutations are present in 5% to 18% of AML \[[@B59]--[@B62]\]. They are associated with*ASXL1* \[[@B59]\],*MLL*^PTD^ \[[@B62]\], and*IDH1*/*IDH2* mutations \[[@B62]\] and are essentially mutually exclusive of*NPM1* mutations \[[@B59], [@B62]\].*RUNX1* mutations were found to be associated with resistance to chemotherapy, inferior DFS, EFS \[[@B59], [@B61], [@B62]\], and OS \[[@B59]--[@B62]\]. More importantly,*RUNX1* mutations were deemed to be an independent prognostic marker for shorter EFS in multivariable analysis \[[@B62]\]. An explorative subgroup analysis demonstrated that*RUNX1*-mutated AML patients benefited from allo-HSC in terms of RFS \[[@B62]\].

4.2. *MLL*^PTD^ {#sec4.2}
---------------

The*MLL*(Mixed Lineage Leukemia) gene, located on chromosome 11q23, is frequently involved in translocations that recur in AML and have been classified into an individual subgroup, AML with*MLL* fusion genes, t(x;11)(x;23) \[[@B18]\]. MLL fusion proteins are capable of transforming normal hematopoietic stem cells into malignant leukemic stem cells \[[@B63]\]. A*MLL* partial tandem duplication (*MLL*^PTD^), the result of a tandem duplication of an internal portion of the*MLL* gene that spans either exons 2 to 6 or exons 2 to 8, is present in approximately 10% of CN-AML \[[@B64], [@B65]\].*MLL*^PTD^ mutation has been identified as a poor prognostic factor for EFS \[[@B60], [@B66], [@B67]\] and OS \[[@B27], [@B41], [@B60], [@B67]\]. Furthermore, it is clear that the OS was shortened when the intermediate-risk group patients had mutated*MLL*^PTD^ regardless of the presence of*FLT3*^ITD^ \[[@B27]\].

4.3. *ASXL1* {#sec4.3}
------------

The*ASXL1* (additional sex combs like-1) gene is a human homologue of the*Drosophila* additional sex combs*(Asx)* gene, which is highly conserved across multiple species. The*ASXL1* protein functions in both epigenetic activation and repression of gene transcription \[[@B68]--[@B70]\]. Its regulation of histone modification affects hematopoietic stem cell pool maintenance and its loss causes severe defects in HSC development \[[@B71], [@B72]\].*ASXL1* mutations are more common in the aberrant karyotypes, the elderly, and MDS-associated and secondary AML \[[@B73]--[@B77]\], while 9--12% of*ASXL1* mutations are detected in cytogenetically normal AML \[[@B75]--[@B77]\].*NPM1* and*ASXL1* mutations appear to be mutually exclusive \[[@B76]--[@B78]\]. Several studies have shown that AML patients with*ASXL1* mutations had worse outcomes when compared to those without these mutations \[[@B27], [@B60], [@B75]\]. Specifically in CN-AML,*ASXL1* mutations were associated with inferior complete remission, DFS, OS, and EFS \[[@B77]\].

4.4. *BCOR* {#sec4.4}
-----------

The*BCOR* (*BCL6* corepressor) gene is located on chromosome X and encodes a nuclear protein that is a key transcriptional regulator of hematopoiesis \[[@B79]\]. Studies demonstrated that normal*BCOR* retains hematopoietic stem cells in a quiescent, undifferentiated state and loss-of-function*BCOR* mutations result in enhanced HSC cell proliferation and differentiation \[[@B80]\].*BCOR* mutations occur in 3.8% of CN-AML, and*DNMT3A* mutations are detected in 43.5% of these patients.*BCOR* mutations tend to be associated with an inferior EFS and OS \[[@B81]\].

4.5. *PHF6* {#sec4.5}
-----------

The*PHF6* (plant homeodomain finger 6) gene, also located on chromosome X, plays a key role in chromatin remodeling \[[@B82]\].*PHF6* mutations are found in approximately 3% of adult AML and confer worse OS in intermediate-risk patients that are*FLT3*^ITD^ negative \[[@B27]\].

5. AML with*CEBPA*^**biallelic**^ Mutation {#sec5}
==========================================

The*CEBPA* gene is located on chromosome 19 band q13.11 and encodes a 42 kDa size protein that is a member of the basic region leucine zipper transcription factor family \[[@B83]\]. Normal function of*CEBPA* is crucial in maintaining adult hematopoietic stem cell in a quiescent state and*CEBPA* gene knockout in mice results in impaired HSC differentiation \[[@B84]\]. The CEBPA protein is expressed in myelomonocytic cells and is critical for neutrophil development \[[@B83]\]. Mutated*CEBPA* regulates Sox4 expression which affects self-renewal of leukemic stem cells \[[@B85]\]. The frequency of*CEBPA* mutations is reported to range from 7% to 22% in patients with AML \[[@B86]\] and 15% to 18% in CN-AML \[[@B87], [@B88]\]. About two-thirds of*CEBPA*-mutated patients are biallelic-mutated (*CEBPA*^biallelic^), and the remaining one-third carry a single mutation (*CEBPA*^monoallelic^). In a meta-analysis of 10 clinical studies covering 6219 patients,*CEBPA*^biallelic^ mutation was found to be associated with favorable clinical outcomes with regard to EFS and OS in patients with AML or CN-AML; conversely, no significant difference was found between*CEBPA*^monoallelic^ mutation and wild-type*CEBPA* in patients with AML or CN-AML \[[@B86]\]. In a long-term follow-up study (median follow-up time of 9.8 years), patients with*CEBPA*^biallelic^ mutations showed longer OS, longer relapse-free survival, and a lower cumulative incidence of relapse compared to those with*CEBPA*^monoallelic^ mutation. The ten-year OS rate for patients ≤60 years and with*CEBPA*^biallelic^ mutation was 81%.*CEBPA*^biallelic^-mutated AML was associated with*TET2* mutation in 34% of the patients, and the combination resulted in significantly worse OS, whereas it was associated with*GATA2* (GATA binding protein 2, a transcription factor) mutation, found in 21% of*CEBPA*^biallelic^-mutated AML, resulting in improved OS \[[@B89]\].

6. AML with*IDH2*^**R172**^ Mutation {#sec6}
====================================

*IDH2* ^R172^ is a distinct*IDH2* mutation that occurs in AML with a frequency of 1--3% \[[@B18], [@B52], [@B90]\]. Unlike*IDH2*^R140^ that significantly correlates with*NPM1* mutation,*IDH2*^R172^ is generally not associated with other molecular mutations. The gene expression and DNA methylation profiles of*IDH2*^R172^-mutated AML differ from those of other IDH mutations and lead to more severe aberrations in metabolic activity \[[@B91], [@B92]\]. Thus,*IDH2*^R172^ mutation has been defined as a unique subgroup in the new classification scheme \[[@B18]\]. In previous studies,*IDH2*^R172^ mutation was associated with a higher relapse rate and lower OS that were comparable with those of the adverse-risk cytogenetics patients \[[@B52], [@B90]\]. In this most recent study, however, the presence of*IDH2*^R172^ mutation was associated with a favorable prognosis with regard to OS, similar to patients with*NPM1*-mutated AML \[[@B18]\].

7. Conclusions and Future Directions {#sec7}
====================================

The progress in AML risk stratification using next-generation sequencing technologies over the past decade has been truly remarkable. As an example, the identification of*NPM1*- or*CEBPA*^biallelic^-mutated CN-AML to have favorable risk has significantly impacted the clinical management of these patient groups. The novel AML classification system proposed by Papaemmanuil et al. has been especially valuable in organizing the growing array of AML mutations in terms of additive effects on prognosis. As an example, the subgroup "AML with*NPM1* mutation" is the largest subgroup and has a large number of comutations. The different comutation combinations do not have a strictly additive effect on clinical outcomes indicating further risk stratification in this group is necessary. Conversely, the subgroup "AML with mutated chromatin, RNA-splicing genes, or both" is more consistent as an adverse prognostic group, at least among the five genetic mutations we reviewed here:*RUNX1*,*MLL*^PTD^,*ASXL1, BCOR, and PHF6*. A central theme of this adverse-risk group is that the majority of these genes have roles in maintaining normal HSC quiescence by their epigenetic regulation and their mutations result in transformation of HSC into leukemic stem cells. These malignant stem cells, in turn, are thought to be the wellspring of leukemic cell expansion, likely directly responsible for the relapsing nature of AML. Of note, mutations in epigenetic modifiers or regulators such as*DNMT3A*,*TET2*, and*IDH1*/*2* alter normal HSC quiescent state and prime HSC to a preleukemic state \[[@B93]\]. These epigenetic factors function as stem cell regulators and impact DFS ([Figure 1](#fig1){ref-type="fig"}). This observation may be true beyond AML and therapies targeting epigenetic modifiers or stem cell regulating factors may hold promise in improving disease-free survival of patients with other hematologic malignancies. These observations of recurrent AML mutations and comutation patterns await validation in larger prospective clinical trials. Regardless, this new classification strategy is an important step forward in understanding the molecular complexity of AML and has the potential to yield many new therapeutic targets to be exploited to someday eradicate this aggressive disease.
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![Kaplan-Meier curves for disease-free survival according to the presence or absence of the specific gene alterations. Gene alterations include mutations, deletions, fusions, and gene amplifications. All the alterations for*IDH1* are mutations. Over 95% of the alterations are mutations for*DNMT3A*,*TET2,* and*FLT3*. The rest of the alterations are multiple alterations for*DNMT3A* and*TET2* and deletions for*FLT3*. Database used for analysis is TCGA, NEJM 2013 \[[@B94]\]. The cBio Cancer Genomics Portal was used for the analysis \[[@B95]\] (<http://cbioportal.org>).](SCI2017-6962379.001){#fig1}

###### 

Molecular classification of CN-AML and clinical outcomes.

  --------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  AML with *NPM1* mutation                                   
   *NPM1*^*∗*^                                              Better EFS and OS \[[@B29]--[@B32]\]; better CRR, high RR with EFS or OS benefits \[[@B33]\]; better OS \[[@B34]\]
   *NPM1*/*DNMT3A*                                          Worse OS \[[@B41]\]
   *NPM1*/*DNMT3A*/*FLT3*^ITD^                              Worse OS \[[@B18]\]
   *NPM1*/*DNMT3A*/*NRAS*^G12/13^                           Better OS \[[@B18]\]
   *NPM1*/*TET2*^*∗*^                                       Worse CRR, EFS, DFS, and OS \[[@B50]\]; no impact on outcomes \[[@B41]\]
  *NPM1*/*IDH1*^*∗*^ or *NPM1*/*IDH2*^R140*∗*^              Worse OS \[[@B55]\]; better OS \[[@B27], [@B52]\]
                                                            
  AML with mutated chromatin, RNA-splicing genes, or both   
   *RUNX1*                                                  Worse EFS, DFS \[[@B59], [@B61], [@B62]\]; worse OS \[[@B59]--[@B62]\]
   *MLL*^PTD^                                               Worse EFS \[[@B60], [@B66], [@B67]\]; worse OS \[[@B27], [@B41], [@B60], [@B67]\]
   *ASXL1*                                                  Worse outcomes \[[@B27], [@B60], [@B75]\]; worse CR, EFS, DFS, and OS \[[@B77]\]
   *BCOR*                                                   Worse EFS and OS \[[@B81]\]
   *PHF6*^*∗*^                                              Worse OS \[[@B27]\]
  AML with *CEBPA*^biallelic^ mutation                       
   *CEBPA*^biallelic^                                       Better EFS and OS \[[@B86]\]
   *CEBPA*^biallelic^/*TET2*                                Worse OS \[[@B89]\]
   *CEBPA*^biallelic^/*GATA2*                               Better OS \[[@B89]\]
                                                            
  AML with *IDH2*^R172^ mutation                            Worse RR and OS \[[@B52], [@B90]\]; better OS \[[@B18]\]
  --------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------

EFS: event-free survival; OS: overall survival; CRR: complete remission rate; RR: relapse rate; DFS: disease-free survival.

^*∗*^Without *FLT3*^ITD^.

###### 

Cooccurrent or mutually exclusive alterations and their significance in genes of interests.

  Gene A     Gene B     *P* value   Odds ratio   Association                            
  ---------- ---------- ----------- ------------ ------------------------------------- -------------
  *ASXL1*    *IDH2*     0.003       2.241        Tendency towards cooccurrence         Significant
  *IDH1*     *DNMT3A*   0.005       1.266        Tendency towards cooccurrence         Significant
  *TET2*     *DNMT3A*   0.01        1.156        Tendency towards cooccurrence         Significant
  *DNMT3A*   *FLT3*     0.035       0.713        Tendency towards cooccurrence         Significant
  *KMT2A*    *DNMT3A*   0.042       −1.169       Tendency towards mutual exclusivity   Significant
  *IDH2*     *KMT2A*    0.056       1.052        Tendency towards cooccurrence         Marginal

Database used for analysis is TCGA, NEJM 2013 \[[@B94]\]. The database contains all 166 complete tumors of AML. Query was performed on 10 genes which include *ASXL1*, *BCOR*, *TET2*, *IDH1*, *IDH2*, *RUNX1*, *PHF6*, *KMT2A (MLL)*, *DNMT3A*, and *FLT3*. The query results contain 23 gene pairs with mutually exclusive alterations (1 significant) and 22 gene pairs with cooccurrent alterations (4 significant, 1 marginal).

[^1]: Academic Editor: Armand Keating
